[go: up one dir, main page]

PL3995135T3 - Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym - Google Patents

Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym

Info

Publication number
PL3995135T3
PL3995135T3 PL20206800.3T PL20206800T PL3995135T3 PL 3995135 T3 PL3995135 T3 PL 3995135T3 PL 20206800 T PL20206800 T PL 20206800T PL 3995135 T3 PL3995135 T3 PL 3995135T3
Authority
PL
Poland
Prior art keywords
tapentadol
dosage form
acid salt
tartaric acid
release dosage
Prior art date
Application number
PL20206800.3T
Other languages
English (en)
Inventor
Ulrike Bertram
Ulrich Reinhold
Christian Grosse
Carmen HARTMANN
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73343829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3995135(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL3995135T3 publication Critical patent/PL3995135T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20206800.3T 2020-11-10 2020-11-10 Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym PL3995135T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20206800.3A EP3995135B1 (de) 2020-11-10 2020-11-10 Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure

Publications (1)

Publication Number Publication Date
PL3995135T3 true PL3995135T3 (pl) 2022-10-03

Family

ID=73343829

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20206800.3T PL3995135T3 (pl) 2020-11-10 2020-11-10 Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym

Country Status (10)

Country Link
EP (1) EP3995135B1 (pl)
AU (1) AU2021201353B1 (pl)
DK (1) DK3995135T3 (pl)
ES (1) ES2927147T3 (pl)
HR (1) HRP20221136T1 (pl)
HU (1) HUE059465T2 (pl)
LT (1) LT3995135T (pl)
PL (1) PL3995135T3 (pl)
PT (1) PT3995135T (pl)
RS (1) RS63521B1 (pl)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
JP5700904B2 (ja) 2004-07-01 2015-04-15 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング （１ｒ，２ｒ）−３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノールを含有する乱用防止経口投与形態物
KR20090074263A (ko) 2006-10-27 2009-07-06 얀센 파마슈티카 엔.브이. 건식 과립화 약제학적 조성물 및 이의 제조방법
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
MX341072B (es) 2010-07-23 2016-08-05 Grünenthal Gmbh * Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
WO2015014980A1 (en) 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP3122336A4 (en) * 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release biphasic matrix solid dosage form
US10182992B2 (en) * 2014-04-07 2019-01-22 Patheon Softgels Inc. Abuse-deterrent controlled release formulations
EP2942054A1 (en) 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
WO2017085734A1 (en) 2015-11-17 2017-05-26 Msn Laboratories Private Limited Crystalline forms of tapentadol salts and process for preparation thereof
US20180369151A1 (en) * 2017-05-29 2018-12-27 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
CN111346077B (zh) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 一种他喷他多透皮给药的药物组合物及其制备方法和应用
EP3875080A1 (en) * 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt

Also Published As

Publication number Publication date
HRP20221136T1 (hr) 2022-11-25
HUE059465T2 (hu) 2022-11-28
EP3995135A1 (de) 2022-05-11
DK3995135T3 (da) 2022-08-22
LT3995135T (lt) 2022-08-25
EP3995135B1 (de) 2022-07-13
RS63521B1 (sr) 2022-09-30
AU2021201353B1 (en) 2022-04-21
ES2927147T3 (es) 2022-11-02
PT3995135T (pt) 2022-09-08

Similar Documents

Publication Publication Date Title
IL254854A0 (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
PL3720838T3 (pl) Sole organicznych kwasów sulfonowych i estrów aminokwasów i sposoby ich wytwarzania
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
HRP20241103T1 (hr) 2,4-di-(skupina koja sadrži dušik)-supstituirani pirimidinski spoj i postupak pripreme i njegova upotreba
ZA202007701B (en) Triesters of cyclohexanetripropionic acid
EA201691538A1 (ru) Способ получения солей вортиоксетина
IL199608A (en) Aqueous composition containing ammonium salt of abscisic acid - s - (+) and a method for its preparation
IL258117A (en) Hydrophilic gel for local administration of 5-amino levulinic acid
PL3995135T3 (pl) Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym
DK3377049T3 (en) Crystalline forms of tapentadol salts and process for preparation thereof
CA3245315A1 (en) L(+) TARTARIC ACID CABOZANTINIB SALT AND ITS SOLID FORMS
HUE064779T2 (hu) A tapentadol foszforsav sójának elnyújtott hatóanyag-leadást biztosító adagolási formája
GR1008821B (el) Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου
IL290625A (en) Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use
EP2247569A4 (en) ACID TOLTEROOD SALT WITH EFFECTIVE STABILITY FOR TRANSDERMAL ACTIVE COMPOSITION SYSTEM
SI3731817T1 (sl) Farmacevtski sestavek farmacevtsko sprejemljive adicijske soli lenalidomida s kislino
MX343986B (es) Composiciones farmaceuticas estabilizadas que comprenden sales de rasagilina.
PL3882244T3 (pl) ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCH
GB202006715D0 (en) Methods of making nucleioc acid nanostructures
EP4067332C0 (de) Verfahren zur herstellung von aluminiumsalzen einer fettsäure
CA3256768A1 (en) PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID
CA3258561A1 (en) ORAL LIQUID COMPOSITION BASED ON AMINO ACID
GB202017267D0 (en) Process of preparing active pharmaceutical ingredient salts
IL307786A (en) Sterile aqueous choline salt formulations
PL4071143T3 (pl) Krystaliczna postać monohydratu fumaranu dimetyloaminomicheliolidu